Following the close of the market on Tuesday, Penumbra announced the U.S. Food and Drug Administration (FDA) advised recall of their catheter device resulting from 14 reported patient deaths, among other patient hemorrhages, strokes, and vessel damages. The recall is presumed to cost the company a revenue loss of $20 million in the fourth quarter. CEO Adam Elsesser predicts some sale losses will be regained as patients switch to other company products, and that their U.S stroke market share will recover.  

Read more here.  

More on: